請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78083
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳彥榮(Edward chern) | |
dc.contributor.author | Hsing-Yi Yu | en |
dc.contributor.author | 余星億 | zh_TW |
dc.date.accessioned | 2021-07-11T14:41:42Z | - |
dc.date.available | 2021-11-02 | |
dc.date.copyright | 2016-11-02 | |
dc.date.issued | 2016 | |
dc.date.submitted | 2016-08-19 | |
dc.identifier.citation | 1. Kelly SJ. Studies of the developmental potential of 4- and 8-cell stage mouse blastomeres. J Exp Zool. 1977;200(3):365-76.
2. Ilic D, Polak JM. Stem cells in regenerative medicine: introduction. Br Med Bull. 2011;98:117-26. 3. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282(5391):1145-7. 4. Takahashi K, Yamanaka S. A decade of transcription factor-mediated reprogramming to pluripotency. Nat Rev Mol Cell Biol. 2016;17(3):183-93. 5. Gurdon JB. Adult frogs derived from the nuclei of single somatic cells. Dev Biol. 1962;4:256-73. 6. King TJ, Briggs R. Changes in the Nuclei of Differentiating Gastrula Cells, as Demonstrated by Nuclear Transplantation. Proc Natl Acad Sci U S A. 1955;41(5):321-5. 7. Stadtfeld M, Hochedlinger K. Induced pluripotency: history, mechanisms, and applications. Genes Dev. 2010;24(20):2239-63. 8. Wilmut I, Schnieke AE, McWhir J, Kind AJ, Campbell KH. Viable offspring derived from fetal and adult mammalian cells. Nature. 1997;385(6619):810-3. 9. Wakayama T, Perry AC, Zuccotti M, Johnson KR, Yanagimachi R. Full-term development of mice from enucleated oocytes injected with cumulus cell nuclei. Nature. 1998;394(6691):369-74. 10. Tada M, Takahama Y, Abe K, Nakatsuji N, Tada T. Nuclear reprogramming of somatic cells by in vitro hybridization with ES cells. Curr Biol. 2001;11(19):1553-8. 11. Schneuwly S, Klemenz R, Gehring WJ. Redesigning the body plan of Drosophila by ectopic expression of the homoeotic gene Antennapedia. Nature. 1987;325(6107):816-8. 12. Davis RL, Weintraub H, Lassar AB. Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell. 1987;51(6):987-1000. 13. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-76. 14. Ben-David U, Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer. 2011;11(4):268-77. 15. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature. 2007;448(7151):313-7. 16. Soldner F, Hockemeyer D, Beard C, Gao Q, Bell GW, Cook EG, et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell. 2009;136(5):964-77. 17. Woltjen K, Michael IP, Mohseni P, Desai R, Mileikovsky M, Hamalainen R, et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature. 2009;458(7239):766-70. 18. Lee AS, Tang C, Rao MS, Weissman IL, Wu JC. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nat Med. 2013;19(8):998-1004. 19. Stadtfeld M, Nagaya M, Utikal J, Weir G, Hochedlinger K. Induced pluripotent stem cells generated without viral integration. Science. 2008;322(5903):945-9. 20. Jia F, Wilson KD, Sun N, Gupta DM, Huang M, Li Z, et al. A nonviral minicircle vector for deriving human iPS cells. Nat Methods. 2010;7(3):197-9. 21. Ban H, Nishishita N, Fusaki N, Tabata T, Saeki K, Shikamura M, et al. Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors. Proc Natl Acad Sci U S A. 2011;108(34):14234-9. 22. Warren L, Manos PD, Ahfeldt T, Loh YH, Li H, Lau F, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell. 2010;7(5):618-30. 23. Miyoshi N, Ishii H, Nagano H, Haraguchi N, Dewi DL, Kano Y, et al. Reprogramming of mouse and human cells to pluripotency using mature microRNAs. Cell Stem Cell. 2011;8(6):633-8. 24. Kim D, Kim CH, Moon JI, Chung YG, Chang MY, Han BS, et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell. 2009;4(6):472-6. 25. Hou P, Li Y, Zhang X, Liu C, Guan J, Li H, et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science. 2013;341(6146):651-4. 26. Han J, Yuan P, Yang H, Zhang J, Soh BS, Li P, et al. Tbx3 improves the germ-line competency of induced pluripotent stem cells. Nature. 2010;463(7284):1096-100. 27. Zhao Y, Yin X, Qin H, Zhu F, Liu H, Yang W, et al. Two supporting factors greatly improve the efficiency of human iPSC generation. Cell Stem Cell. 2008;3(5):475-9. 28. Tsubooka N, Ichisaka T, Okita K, Takahashi K, Nakagawa M, Yamanaka S. Roles of Sall4 in the generation of pluripotent stem cells from blastocysts and fibroblasts. Genes Cells. 2009;14(6):683-94. 29. Feng B, Jiang J, Kraus P, Ng JH, Heng JC, Chan YS, et al. Reprogramming of fibroblasts into induced pluripotent stem cells with orphan nuclear receptor Esrrb. Nat Cell Biol. 2009;11(2):197-203. 30. Judson RL, Babiarz JE, Venere M, Blelloch R. Embryonic stem cell-specific microRNAs promote induced pluripotency. Nat Biotechnol. 2009;27(5):459-61. 31. Worringer KA, Rand TA, Hayashi Y, Sami S, Takahashi K, Tanabe K, et al. The let-7/LIN-41 pathway regulates reprogramming to human induced pluripotent stem cells by controlling expression of prodifferentiation genes. Cell Stem Cell. 2014;14(1):40-52. 32. Kawamura T, Suzuki J, Wang YV, Menendez S, Morera LB, Raya A, et al. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature. 2009;460(7259):1140-4. 33. Marion RM, Strati K, Li H, Murga M, Blanco R, Ortega S, et al. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature. 2009;460(7259):1149-53. 34. Urbach A, Schuldiner M, Benvenisty N. Modeling for Lesch-Nyhan disease by gene targeting in human embryonic stem cells. Stem Cells. 2004;22(4):635-41. 35. Eiges R, Urbach A, Malcov M, Frumkin T, Schwartz T, Amit A, et al. Developmental study of fragile X syndrome using human embryonic stem cells derived from preimplantation genetically diagnosed embryos. Cell Stem Cell. 2007;1(5):568-77. 36. Briggs JA, Sun J, Shepherd J, Ovchinnikov DA, Chung TL, Nayler SP, et al. Integration-free induced pluripotent stem cells model genetic and neural developmental features of down syndrome etiology. Stem Cells. 2013;31(3):467-78. 37. Avior Y, Sagi I, Benvenisty N. Pluripotent stem cells in disease modelling and drug discovery. Nat Rev Mol Cell Biol. 2016;17(3):170-82. 38. Tan Q, Lui PP, Rui YF, Wong YM. Comparison of potentials of stem cells isolated from tendon and bone marrow for musculoskeletal tissue engineering. Tissue Eng Part A. 2012;18(7-8):840-51. 39. Nori S, Okada Y, Yasuda A, Tsuji O, Takahashi Y, Kobayashi Y, et al. Grafted human-induced pluripotent stem-cell-derived neurospheres promote motor functional recovery after spinal cord injury in mice. Proc Natl Acad Sci U S A. 2011;108(40):16825-30. 40. Liu H, Kim Y, Sharkis S, Marchionni L, Jang YY. In vivo liver regeneration potential of human induced pluripotent stem cells from diverse origins. Sci Transl Med. 2011;3(82):82ra39. 41. De Jong WH, Borm PJ. Drug delivery and nanoparticles:applications and hazards. Int J Nanomedicine. 2008;3(2):133-49. 42. Niidome T, Yamagata M, Okamoto Y, Akiyama Y, Takahashi H, Kawano T, et al. PEG-modified gold nanorods with a stealth character for in vivo applications. J Control Release. 2006;114(3):343-7. 43. Liu Y, Miyoshi H, Nakamura M. Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int J Cancer. 2007;120(12):2527-37. 44. Meng F, Zhong Y, Cheng R, Deng C, Zhong Z. pH-sensitive polymeric nanoparticles for tumor-targeting doxorubicin delivery: concept and recent advances. Nanomedicine (Lond). 2014;9(3):487-99. 45. Rahimi M, Kilaru S, Sleiman GE, Saleh A, Rudkevich D, Nguyen K. Synthesis and Characterization of Thermo-Sensitive Nanoparticles for Drug Delivery Applications. J Biomed Nanotechnol. 2008;4(4):482-90. 46. Duncan R. Polymer conjugates for tumour targeting and intracytoplasmic delivery. The EPR effect as a common gateway? Pharm Sci Technolo Today. 1999;2(11):441-9. 47. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008;60(15):1615-26. 48. Nair LS, Laurencin CT. Biodegradable polymers as biomaterials. Progress in Polymer Science. 2007;32(8-9):762-98. 49. Place ES, George JH, Williams CK, Stevens MM. Synthetic polymer scaffolds for tissue engineering. Chem Soc Rev. 2009;38(4):1139-51. 50. Elzoghby AO, Samy WM, Elgindy NA. Protein-based nanocarriers as promising drug and gene delivery systems. J Control Release. 2012;161(1):38-49. 51. Aramwit P, Jaichawa N, Ratanavaraporn J, Srichana T. A comparative study of type A and type B gelatin nanoparticles as the controlled release carriers for different model compounds. Materials Express. 2015;5(3):241-8. 52. Little SR, Kohane DS. Polymers for intracellular delivery of nucleic acids. Journal of Materials Chemistry. 2008;18(8):832-41. 53. Ma Y-q. Insights into the endosomal escape mechanism via investigation of dendrimer–membrane interactions. Soft Matter. 2012;8(23):6378-84. 54. Kuo W-T, Huang H-Y, Chou M-J, Wu M-C, Huang Y-Y. Surface Modification of Gelatin Nanoparticles with Polyethylenimine as Gene Vector. Journal of Nanomaterials. 2011;2011:1-5. 55. Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014;157(6):1262-78. 56. Mojica FJ, Diez-Villasenor C, Soria E, Juez G. Biological significance of a family of regularly spaced repeats in the genomes of Archaea, Bacteria and mitochondria. Mol Microbiol. 2000;36(1):244-6. 57. Tang TH, Bachellerie JP, Rozhdestvensky T, Bortolin ML, Huber H, Drungowski M, et al. Identification of 86 candidates for small non-messenger RNAs from the archaeon Archaeoglobus fulgidus. Proc Natl Acad Sci U S A. 2002;99(11):7536-41. 58. Mojica FJ, Diez-Villasenor C, Garcia-Martinez J, Soria E. Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. J Mol Evol. 2005;60(2):174-82. 59. Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science. 2007;315(5819):1709-12. 60. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339(6121):819-23. 61. Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell. 2013;152(5):1173-83. 62. Konermann S, Brigham MD, Trevino AE, Hsu PD, Heidenreich M, Cong L, et al. Optical control of mammalian endogenous transcription and epigenetic states. Nature. 2013;500(7463):472-6. 63. Cheng AW, Wang H, Yang H, Shi L, Katz Y, Theunissen TW, et al. Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system. Cell Res. 2013;23(10):1163-71. 64. Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell. 2013;154(2):442-51. 65. Coester CJ, Langer K, van Briesen H, Kreuter J. Gelatin nanoparticles by two step desolvation--a new preparation method, surface modifications and cell uptake. J Microencapsul. 2000;17(2):187-93. 66. Liang X, Potter J, Kumar S, Zou Y, Quintanilla R, Sridharan M, et al. Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection. J Biotechnol. 2015;208:44-53. 67. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010;75(1):1-18. 68. Zuris JA, Thompson DB, Shu Y, Guilinger JP, Bessen JL, Hu JH, et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat Biotechnol. 2015;33(1):73-80. 69. Varkouhi AK, Scholte M, Storm G, Haisma HJ. Endosomal escape pathways for delivery of biologicals. J Control Release. 2011;151(3):220-8. 70. Kakimoto S, Hamada T, Komatsu Y, Takagi M, Tanabe T, Azuma H, et al. The conjugation of diphtheria toxin T domain to poly(ethylenimine) based vectors for enhanced endosomal escape during gene transfection. Biomaterials. 2009;30(3):402-8. 71. Kane JF. Effects of rare codon clusters on high-level expression of heterologous proteins in Escherichia coli. Curr Opin Biotechnol. 1995;6(5):494-500. 72. Kim S, Lee SB. Rare codon clusters at 5'-end influence heterologous expression of archaeal gene in Escherichia coli. Protein Expr Purif. 2006;50(1):49-57. 73. Liu X, Sun H, Qi J, Wang L, He S, Liu J, et al. Sequential introduction of reprogramming factors reveals a time-sensitive requirement for individual factors and a sequential EMT-MET mechanism for optimal reprogramming. Nat Cell Biol. 2013;15(7):829-38. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78083 | - |
dc.description.abstract | 誘導式多能性幹細胞 (iPSC) 在再生醫學領域中具備極佳的潛能,它可 應用在疾病的機制探討、新藥開發、幹細胞治療以及組織工程的研究之中。與胚胎幹細胞不同,誘導式多能性幹細胞避開了道德爭議的問題。然而第一代以病毒製備的誘導式多能性幹細胞面臨基因突變的可能性與致癌性,從而陸續有研究欲改善製備的方法。以蛋白質為基礎的方法相較於其他非DNA相關的方法具備較高的穩定性,但是針對細胞的蛋白質輸送現今依然面臨挑戰。
藥物輸送系統相較於傳統的藥物劑型具備許多優點:保護藥物、增加在血液循環的半衰期、控制釋放速率以及主動標靶等等。奈米粒子是常見的一種藥物輸送系統,蛋白質被奈米粒子攜帶而進入細胞之中可以大幅增加輸送的效率,並且保護蛋白質不受酵素破壞。 利用明膠聚丙烯亞胺奈米粒子攜帶以誘導細胞再程序化之功能蛋白質進入人類纖維細胞中,以製備絕對安全的誘導式多能性幹細胞。在研究中我首先證明了明膠聚丙烯亞胺奈米粒子蛋白傳送系統的可行性。我製備出的奈米粒子,顆粒直徑約為100 nm,表面界面電位為 +43.2。細胞毒性測試中顯示奈米粒子的毒性是可接受的。在BSA結合實驗中證明明膠聚丙烯亞胺奈米粒子,有能力吸附BSA在粒子表面,並且在重量比為1:1時有最大的結合效率。為了進行近一步蛋白質功能測試,我利用大腸桿菌系統表現並純化出His-eGFP的蛋白質。利用明膠聚丙烯亞胺奈米粒子投遞His-eGFP至細胞中的實驗顯示,確實蛋白質可以順利進入細胞內部還維持良好功能,順利表現綠色螢光。在建立誘導細胞再程序化之蛋白質實驗中,在BL21菌株中始終得不到理想的蛋白質表現量。再BL21 StarTM (DE3)的菌株中表現下,目標蛋白之表現量有顯著的上升。利用冷光素酶檢測法,確定設計標的Nanog啟動子的小RNA片段能夠引導在程序蛋白開啟基因表現。未來,需要進行再程序化之功能蛋白質的細胞遞送實驗進一步測試其功能性。最終期望以新方法生產安全的誘導式多能性幹細胞,並且在未來應用在臨床上。 | zh_TW |
dc.description.abstract | Induced pluripotent stem cell (iPSC) possesses high potentials in regeneration medicine. It has been used in several applications such as disease mechanism study, drug development, stem cell therapy, and tissue engineering. Because of the problem of ethical controversy which hinders the development of embryonic stem cell research, iPSC is a better platform for the stem cell research. The first generation of iPSC is generated from somatic cells by virus infection. Therefore, the safety issue should be concerned because of the possibility of gene mutation and carcinogenesis. To solve this problem, there has been different ways to generate iPSC. One of them is the protein-based method. The research in protein delivery with efficiency and safety is still under development.
Comparing to the traditional dosage form, drug delivery system has many advantages such as drug protection, the improvement of half-life, controlling release, and active targeting. The nanoparticle is one of drug delivery system, which is reported to enhance the efficiency in protein delivery. In this study, I try to force express Yamanaka factors in Hs68 by protein-based reprogramming proteins (RPs) delivery with Gelatin-PEI nanoparticle to generate the absolutely safe iPSC. First, Gelatin-PEI nanoparticles were produced. The average diameter of them was about 100 nm, and the zeta potential on the surface was +43.2. The MTT assay showed that Gelatin-PEI nanoparticles are safe with the acceptable cytotoxicity. In the experiment of BSA binding assay, Gelatin-PEI nanoparticles could bind with BSA, and the highest efficiency was achieved when the wt/wt equal to 1. For the functional test after delivery, eGFP was cloned and expressed in E.coli system, and then it was purified by Ni-NTA spin column. The last, in the experiment of eGFP delivery into Hs68 cell line, Gelatin-PEI nanoparticle was capable of carrying eGFP, internalizing to Hs68, and helping it escape from endosome. These data indicated Gelatin-PEI nanoparticle is a high potential Nanocarrier in protein delivery. Next, RPs was cloned and expressed in BL21. BL21 StarTM (DE3) strain was used to express RPs with relative high expression level. The small RNA sequence was produced and identified to guide RPs to activate the Nanog-luc gene expression. Further functional tests of RPs delivery system should be evaluated in the future. Overall, I expect to develop a new method to generate iPSC for clinical application. | en |
dc.description.provenance | Made available in DSpace on 2021-07-11T14:41:42Z (GMT). No. of bitstreams: 1 ntu-105-R03b22037-1.pdf: 2117679 bytes, checksum: 660cee676599b66fee6c200b16e3cf9d (MD5) Previous issue date: 2016 | en |
dc.description.tableofcontents | 口試委員會審定書 ………i
致謝 ………iiげ 中文摘要 ………iii こ Abstract iv ご Table of contents vi ざ List of figures すix List of tables ずx Chapter one Introduction 1 1.1 Induced pluripotent stem cells 1 1.1.1 Stem cells 1 1.1.2 Induced pluripotent stem cell: history, development, and application ….2 1.2 Drμg delivery system 7 1.2.1 Nanoparticle 7 1.2.2 Biodegradable polymer 9 1.2.3 Gelatin 9 1.3 CRISPR/Cas9 10 1.3.1 CRISPR/Cas9 regulate gene expression 11 1.4 Research aim 13 Chapter two Materials and methods 14 2.1 Cell culture 14 2.1.1 Cell line 14 2.1.2 Cell culture condition 14 2.2 Plasmid construction 14 2.2.1 Plasmid 14 2.2.2 Polymerase chain reaction (PCR) condition 15 2.2.3 Gel filtration 15 2.2.4 Restriction enzyme digestion 16 2.2.5 Competent cell preparation 16 2.2.6 Ligation and transformation 17 2.3 Plasmid mini-preparation 17 2.4 Plasmid midi preparation 18 2.5 Gelatin-PEI production and characterization 19 2.6 Total protein extraction. 20 2.7 SDS-PAGE and CBR staining. 21 2.8 Western analysis 22 2.9 Affinity chromatography. 23 2.10 Protein concentration determination 24 2.11 Cell viability analysis 24 2.12 BSA binding assay 25 2.13 Intracellular protein delivery of gelatin-PEI nanoparticles 25 2.14 sgRNA template synthesis and in vitro transcription 26 2.15 Nanog promoter luciferase assay with sgNanog delivery 27 Chapter three Result 28 3.1 The properties of Gelatin-PEI nanoparticles 28 3.2 Gelatin-PEI nanoparticle is a vector with low cytotoxicity 28 3.3 Gelatin-PEI nanoparticle is able to bind with BSA 28 3.4 The overexpression and purification of eGFP 29 3.5 The protein delivery capacity of Gelatin-PEI in vitro 30 3.6 The overexpression and purification of dCas9vp160 31 3.7 Small guide RNA function verification 32 Chapter four Conclusion and Discussion 34 Reference 56 Appendix 62 | |
dc.language.iso | en | |
dc.title | 正電奈米粒子作為蛋白質輸送系統之載體以製造人類誘導多能幹細胞之研究 | zh_TW |
dc.title | Cationic nanoparticles as a carrier of protein delivery system to generate induced pluripotent stem cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 104-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 黃楓婷,趙曉梅 | |
dc.subject.keyword | 藥物傳輸系統,奈米粒子,誘導式幹細胞, | zh_TW |
dc.subject.keyword | drug delivery,Nanoparticle,iPSC, | en |
dc.relation.page | 62 | |
dc.identifier.doi | 10.6342/NTU201603319 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2016-08-21 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生化科技學系 | zh_TW |
顯示於系所單位: | 生化科技學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-R03b22037-1.pdf 目前未授權公開取用 | 2.07 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。